¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËÄÒ½¿Æ´óѧ1998ÄêÃâÒßѧ£¨×¨»ù£©£¨²©Ê¿£©
¼¶±ð: ²©Ê¿
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-01-20   

µÚËÄÒ½¿Æ´óѧ1998ÄêÃâÒßѧ£¨×¨»ù£©£¨²©Ê¿£©

µÚËÄÒ½¿Æ´óѧ1998ÄêÃâÒßѧ£¨×¨»ù£©£¨²©Ê¿£© (7q!Z!2  
&a%|L=FY  
  Ò»¡¢Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© v!T%xUb0  
  1¡¢Co-stimulators (or co-stimulating molecules) R z 1&(_Ps  
  2¡¢NK-kB 2J =K\ L  
  3¡¢Immunoglobulin superfamily ^4_)a0Kcm,  
  4¡¢antigen-presenting cell (APC) VS<E?JnbFV  
  5¡¢death domain Qx|m{1~-  
  6¡¢CCR and CXCR *z;4. OX  
  7¡¢Lectin (or mitogen) "tB"C6b  
  8¡¢Clusters of differentiation, CD)  XeDiiI  
  9¡¢B7 family C Fq3  
  10¡¢Cytotoxic T lymphocyte, CTL) _eM\ /(v[  
  11¡¢IL-15 and IL-15 receptor (IL-15R) [ps5;  
  12¡¢MHC restriction = ;#?CAa:  
  13¡¢Affinity-chromatography +uKh]RP  
  14¡¢Cyctosprin A, CsA PXG)?`^NX  
  15¡¢Antibody-dependent cell-mediated cytotoxicity, ADCC) ^%V'l-}/  
1X2MhV  
  ¶þ¡¢¼ò´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£©  0Lmq?D  
  1¡¢ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 js)M c*]&  
  2¡¢ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ \\XvVi:B  
  3¡¢ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ Hj't.lg+j  
NrT!&>M  
  Èý¡¢ÎÊ´ðÌ⣨25·Ö£© o<bZ.t  
  1¡¢Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ iTF`sjL  
  ѪҺ²¡Ñ§×¨Òµ£º Gs;wx_k^  
  2¡¢ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
4+6=? ÕýÈ·´ð°¸:10
°´"Ctrl+Enter"Ö±½ÓÌá½»